LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Lista de Ações・United Therapeutics Corp

United Therapeutics Corp

Fechado

SetorSaúde

569.57 1

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

563.94

Máximo

580.21

Indicadores-chave
By Trading Economics
Rendimento	26M 364M
Vendas	-9.3M 790M
P/E Médio do Setor	20.877 49.8
Margem de lucro	46.102
Funcionários	1,400
EBITDA	61M 524M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+14.7% upside

Dividendos
By Dow Jones
Próximos Ganhos	29 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	3.2B 25B
Abertura anterior	568.57
Fecho anterior	569.57

Sentimento de Notícias

By Acuity

92%

3 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

292.345 / 309.245 Suporte e Resistência

United Therapeutics Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 de mai. de 2026, 23:38 UTC

Conversa de Mercado

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 de mai. de 2026, 23:14 UTC

Conversa de Mercado

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 de mai. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 de mai. de 2026, 10:21 UTC

Ganhos

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 de mai. de 2026, 06:05 UTC

Ganhos

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Still Going Strong -- Barrons.com

8 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 20:49 UTC

Ganhos

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 de mai. de 2026, 20:25 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Net $115M

8 de mai. de 2026, 19:20 UTC

Conversa de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 de mai. de 2026, 19:18 UTC

Ganhos

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 de mai. de 2026, 19:16 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:08 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:05 UTC

Ganhos

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 de mai. de 2026, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 de mai. de 2026, 18:51 UTC

Ganhos

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 de mai. de 2026, 18:49 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 18:41 UTC

Ganhos

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 de mai. de 2026, 17:14 UTC

Ganhos

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 de mai. de 2026, 17:04 UTC

Conversa de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

United Therapeutics Corp Previsão

Preço-alvo

By TipRanks

14.7% parte superior

Previsão para 12 meses

Média 648 USD 14.7%

Máximo 738 USD

Mínimo 516 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para United Therapeutics Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para United Therapeutics Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

292.345 / 309.245Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

3 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.